ADVANCED HEPATOCELLULAR CARCINOMA

This study tests a drug called zanzalintinib in people with advanced liver cancer that has spread or cannot be cured. The trial has two parts: first, finding the safest dose, then checking if it helps control the cancer. About 59 participants will take the drug by mouth, and rese…

This phase 3 trial is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs (atezolizumab and bevacizumab) alone versus the same drugs plus targeted radiation (SBRT). The goal is to see if adding radiation helps pa…

This early-stage study tests a new drug called ALN-BCAT, given alone or with the immunotherapy Keytruda, in people with advanced or metastatic liver cancer that has a specific genetic mutation (WNT pathway). The trial aims to find safe doses and see if the drugs shrink tumors. Ab…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This study tests a new drug called BL-B01D1, alone or with other cancer drugs, in 74 people with advanced liver cancer that has spread. The goal is to see if these combinations can shrink tumors and how safe they are. Participants will receive the drugs through an IV or as pills …

This study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

This early-stage trial tests a new drug called AU409 in 36 people with advanced liver cancers or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug might shrink tumo…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The goal is to find the safest dose and see if the combination can slow or stop tumor growth. About 92 participants wi…

This study tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard two-drug combos for people with advanced liver cancer that cannot be removed by surgery. About 590 adults who have not had prior cancer treatment will participate. The …

This study tests several new drug combinations for people with advanced liver cancer whose first treatment stopped working. It involves 350 adults and uses advanced imaging and genetic tests to find which treatment works best for each person. The goal is to shrink or control the …

This study tests a drug called Becotatug vedotin in 40 adults with advanced liver cancer that has worsened after standard treatments. The goal is to see if it can shrink tumors and help control the disease. Participants receive the drug and are monitored for safety and response.

This study is for people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. It compares two second-line approaches: adding lenvatinib to the original regimen or switching to regorafenib plus a PD-1 inhibitor. The goal is to see which c…

This phase 2 trial is testing whether a combination of two immune-boosting drugs, ligufalimab and cadonilimab, can shrink advanced liver or bile duct cancers that have stopped responding to prior treatments. About 64 adults will receive the drugs by IV every three weeks. The main…

This phase 2 trial tests whether adding celecoxib (a painkiller) to two immunotherapy drugs (durvalumab and tremelimumab) can help control advanced or metastatic liver cancer. About 39 adults with liver cancer that has spread will receive the combination. The goal is to see if it…

This early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…

This study tests a drug called ADI-PEG 20 against a placebo in 300 people with advanced liver cancer that cannot be removed by surgery. Only people with high levels of the amino acid arginine in their blood can join. The goal is to see if the drug helps them live longer by breaki…

This early-stage trial is testing a new treatment called CNCT19 CAR-T cells for people with advanced liver cancer that cannot be removed by surgery or has come back after other treatments. The therapy uses a patient's own immune cells, modified to target cancer cells. The main go…

This phase II trial tests whether giving immune-boosting drugs (durvalumab with or without tremelimumab) after standard radiation can shrink advanced liver cancer that has spread. About 21 adults whose cancer has progressed on or after prior immunotherapy will receive radiation f…

This study compares giving cancer treatment at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their reg…

This study looks at blood samples from 20 people with advanced liver cancer who are starting immunotherapy. Researchers want to find genetic clues in immune cells that can tell if a patient will respond well to treatment. The goal is to better understand why some patients benefit…